tralokinumab

This page shows the latest tralokinumab news and features for those working in and with pharma, biotech and healthcare.

AZ’s Fasenra hit by COPD trial failure

IL-13 inhibitor tralokinumab has been abandoned after three failed late-stage trials, however, while AZ also has an Amgen-partnered thymic stromal lymphopoietin (TSLP) targeting antibody - tezepelumab - in phase III

Latest news

AZ gets EMA green light for severe asthma drug Fasenra

Prospects for IL-13 inhibitor tralokinumab look terminal after three failed late-stage trials, however, and AZ also has an Amgen-partnered thymic stromal lymphopoietin (TSLP) targeting antibody - tezepelumab - in phase
AZ prices severe asthma drug Fasenra below competition

Prospects for IL-13 inhibitor tralokinumab look rocky after two failed late-stage trials, elevating the importance of Fasenra in those plans.
AZ severe asthma drug benralizumab backed by CHMP

Benralizumab has assumed much greater importance for the company since IL-13 inhibitor tralokinumab - another severe asthma candidate - failed two phase III trials.
Setback for AZ as tralokinumab flunks asthma trial

Puts more pressure on AZ’s benralizumab to reach its potential. AstraZeneca’s hopes of bringing severe asthma candidate tralokinumab to market look rocky after it failed two phase III trials. ... Tralokinumab is an inhibitor of interleukin-13 (IL-13),
Roche out-licenses lebrikizumab rights to Dermira

Disappointing results with other IL-13-targeting drugs in asthma - including Pfizer's anrukinzumab and AstraZeneca's tralokinumab - undermined confidence in the approach.

More from news
Approximately 4 fully matching, plus 16 partially matching documents found.

Latest Intelligence

Leo has its eyes on the prize

Its landmark partnership with AstraZeneca and the launch of Kyntheum, the fully-human monoclonal antibody targeting psoriasis, and the phase III hope of tralokinumab for atopic dermatitis are part of an
2016: The year when deal-makers took stock?

Out-partnering deals included the $1.1bn licence to LEO for tralokinumab in skin diseases and the $1bn divestment to Pfizer of its late-stage small molecule anti-infective business.
Deal Watch July 2016

AstraZeneca is developing tralokinumab for severe asthma, where it is in phase III development, and has recently completed a phase IIb study in patients with atopic dermatitis. ... Acquisition. 1, 530. AstraZeneca/ Leo Pharma. Tralokinumab (anti-IL-13)

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Associate Director – Social Healthcare – London: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Freelance Senior Account Manager / Account Director - Healthcare...: £350-400 depending on experience

Health Consultant - Brand Comms: Competitive Salary

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Senior Account Director – Healthcare Advertising – London: Salary TBC

Home-based Senior Medical Writer – Med Ed: Salary TBC

Digital Account Director: Salary TBC

EU Head of Business Development and Client Service: Exceptional packge and bonus

Home based, Senior Medical Writer, Medical Communications: Excellent package

Scientific Director – Medical Communications: Salary TBC

Home-based Medical Writer – Medical Education: Salary TBC

Senior Account Executive – Account Manager – Healthcare Advertis...: £32000 - £43000 Bonus Benfits

Senior Digital Health Specialist – Global Agency: Salary TBC

Freelance AM/ AD Healthcare Advertising: £350-400 depending on experience

Senior Account Manager, Medical Communications, London: Excellent package

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Managing Director – Global Medical Writing & Scientific Exce...: £120-150K

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

AM – Corporate Comms/ Public Affairs/ B2B – Healthcare Focus: Salary TBC

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Programme/ Account Director - Healthcare PR - London: Salary TBC

Account Director, Medical Education: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

Measures for measures: Why pharma’s marketing metrics must close the loop...
Where next in Alzheimer’s disease R&D?: How past failures and emerging biology are reshaping drug development...
Brain power: fresh approaches to Alzheimer’s drug discovery: New alliances are learning from past mistakes and breaking down research barriers...